Accolade, Inc. in brief
Accolade, Inc. is an unlisted company in the Healthcare Information Services industry, based in California, USA. It was founded in 2007. In the year to February 2024 it had sales of $414 M and a net loss of $100 M. It employs about 2,370 people.
Written from the figures on this page, so it changes when they do. The date of each figure is under How current the figures are.
About Accolade, Inc.
Accolade is a Compassionate Advisers, Clinical Expertise and Intelligent Technology company. The headquarters is in USA.
Accolade Annual Total Revenue for year ending Feb-2023 was 363 million USD and and Net loss for year ending Feb-2023 was -459 million USD.
Accolade Annual Total Revenue for year ending Feb-2022 was 310 million USD and and Net loss for year ending Feb-2022 was -123 million USD.
Read moreShow less
As on Feb-2023, Accolade has 2,370 employees.
Accolade, Inc. timeline
- 2007
- 🏁· approximateFounded
- 2010
- ✎Renamed Accolade, Inc.Formerly Accolade LLC.
- •· approximateFirst filing with the US SECThe company's first electronic filing in SEC EDGAR.
- 2020
- 📈Listed on New York Stock Exchange as ACCD
- 🔔Initial public offering on NasdaqFinal prospectus filed with the SEC on 2 July 2020; shares registered for exchange trading on 25 June 2020.
- 2021
- •Legal Entity Identifier issuedLEI 549300PHKG8J7A22NF08 registered.
- 2023
- 💰Record revenue of $414 millionFY2023, the highest of the 6 years on record.
Events of Accolade, Inc. from Wikidata, SEC EDGAR, the GLEIF LEI register and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
More about Accolade, Inc.
- Acquisitions and changes
- Taken over: the company reported a change in control and the delisting of its shares to the SEC on 8 April 2025 (Form 8-K).
Market cap history
World rank over time
Rank in USA: #1,534 (Jan 2021) · #2,247 (Jan 2022) · #2,440 (Dec 2022) · #2,050 (Jul 2023) · #2,138 (Jan 2024)
Key ratios
- P/E ratio
- n/m (loss)
- Price / sales
- —
- Price / book
- —
- Free cash flow yield
- —
- Net margin
- -24.1%
- Operating margin
- -27.6%
- Return on equity
- -22.4%
- Liabilities / assets
- 43.5%
- Net debt
- $-12M
- Revenue growth
- +14.1%
- Revenue per employee
- $175 K
- Profit per employee
- $-42 K
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Feb 2024 | $414M | +14.1% | $-114M | $-100M | -24.1% |
| Feb 2023 | $363M | +17.1% | $-464M | $-460M | -126.6% |
| Feb 2022 | $310M | +82.0% | $-126M | $-123M | -39.7% |
| Feb 2021 | $170M | +28.6% | $-47M | $-51M | -29.7% |
| Feb 2020 | $133M | +39.8% | $-48M | $-51M | -38.8% |
| Feb 2019 | $95M | — | $-54M | $-57M | -59.6% |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Feb 2024 | $-16M | $5M | $-21M | $-1.33 | — |
| Feb 2023 | $-41M | $2M | $-43M | $-6.45 | — |
| Feb 2022 | $-62M | $3M | $-65M | $-1.93 | — |
| Feb 2021 | $-25M | $2M | $-27M | $-1.72 | $0.00 |
| Feb 2020 | $-34M | $3M | $-38M | $-9.13 | — |
| Feb 2019 | $-17M | $1M | $-18M | $-12.17 | — |
Quarterly results
Latest quarter to Nov 2024: revenue $105M (+5.7% on a year earlier), net income $-121M. Lighter bars: fourth quarters worked out from the annual report.
SEC filings
- Apr 8, 20258-KCurrent reportMaterial agreement · Acquisition or disposal completed · Listing notice · Change in control · Directors or officers changed · Bylaws amended
- Mar 27, 20258-KCurrent reportShareholder vote · Regulation FD disclosure
- Jan 10, 202510-QQuarterly report · period to Nov 2024
- Jan 8, 20258-KCurrent reportMaterial agreement · Results of operations · Regulation FD disclosure
- Oct 8, 202410-QQuarterly report · period to Aug 2024
- Oct 8, 20248-KCurrent reportResults of operations
- Aug 7, 20248-KCurrent reportShareholder vote
- Jun 27, 202410-QQuarterly report · period to May 2024
- Jun 27, 20248-KCurrent reportResults of operations
- Jun 21, 2024DEF 14AProxy statement
- Apr 26, 202410-KAnnual report · period to Feb 2024
- Apr 25, 20248-KCurrent reportResults of operations
Official filings of Accolade, Inc. with the US Securities and Exchange Commission.
Annual results
- Revenue
- $414 M
- Operating income
- $-114 M
- Net income
- $-100 M
For year ending February-2024 · source: SEC filing
Balance sheet
- Total assets
- $788 M
- Total liabilities
- $343 M
- Total equity
- $445 M
As of February-2024
Insider trading at Accolade, Inc.#
Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | Cindy KentDirector | Disposal to the company | -10,602 | $7.030 | $75 K | 0 | Form 4 |
| filed | Robert N. CavanaughPresident | Disposal to the company | -222,216 | $7.030 | $1.6 M | 0 | Form 4 |
| filed | Jeffrey S. BrodskyDirector | Disposal to the company | -46,810 | $7.030 | $329 K | 0 | Form 4 |
| filed | Michael W. HiltonDirector | Disposal to the company | -150,946 | $7.030 | $1.1 M | 0 | Form 4 |
| filed | Peter S. KleinDirector | Disposal to the company | -28,329 | $7.030 | $199 K | 0 | Form 4 |
| filed | Stephen H. BarnesChief Financial Officer | Disposal to the company | -306,874 | $7.030 | $2.2 M | 0 | Form 4 |
| filed | Richard EskewEVP General Counsel | Disposal to the company | -66,191 | $7.030 | $465 K | 0 | Form 4 |
| filed | Patricia L. WadorsDirector | Disposal to the company | -27,759 | $7.030 | $195 K | 0 | Form 4 |
Accolade, Inc. scorecard#
Passes 5 of the 14 checks that could be worked out: strongest in growth (4 of 6), weakest in profitability (0 of 5). Fiscal year 2023.
Valuationnot known
Growth4 of 6
Profitability0 of 5
Financial health1 of 2
Shareholder returns0 of 1
Worked out from the statements as filed (sec), the medians of Healthcare Information Services, the 10-year Treasury yield of Nov 20, 2026 and the market cap (too old for the valuation checks, which need one at most 60 days old). A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
Accolade, Inc.: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2023to Feb 29, 2024 | FY 2022to Feb 28, 2023 | FY 2021to Feb 28, 2022 | FY 2020to Feb 28, 2021 | FY 2019to Feb 29, 2020 | FY 2018to Feb 28, 2019 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 414 | 363 | 310 | 170 | 133 | 95 | |
| Selling and marketing | 100 | 99 | 87 | 34 | 30 | 23 | |
| General and administrative | 62 | 81 | 99 | 32 | 26 | 20 | |
| Operating expenses | 307 | 628 | 267 | 123 | 107 | 88 | |
| Operating income | −114 | −464 | −126 | −47 | −48 | −54 | |
| Other non-operating income (expense) | 9.9 | −0.0 | −0.1 | −0.1 | −0.1 | −0.1 | |
| Income before tax | −99 | −463 | −129 | −51 | −51 | −56 | |
| Income tax | 1.2 | −3.6 | −5.6 | 0.0 | 0.1 | 0.1 | |
| Net income including minority interests | — | −460 | −123 | −51 | −51 | −56 | |
| Net income attributable to shareholders | −100 | −460 | −123 | −51 | −51 | −56 | |
| Earnings per share, basic | -1.33 | -6.45 | -1.93 | -1.72 | -9.13 | -12.17 | |
| Earnings per share, diluted | -1.33 | -6.45 | -1.93 | -1.72 | -9.13 | -12.17 | |
| Shares, weighted average (basic) | 75 | 71 | 64 | 29 | 5.6 | — | |
| Shares, weighted average (diluted) | 75 | 71 | 64 | 29 | 5.6 | 4.6 | |
| Dividends per share | — | — | — | 0.00 | — | — | |
| Balance sheet | |||||||
| Cash and cash equivalents | 186 | 321 | 366 | 434 | 33 | 43 | |
| Receivables | 22 | 23 | 21 | 9.1 | 0.3 | — | |
| Other current assets | 16 | 14 | 9.5 | 6.0 | 13 | — | |
| Current assets | 285 | 366 | 409 | 454 | 49 | — | |
| Property, plant and equipment | 19 | 15 | 12 | 9.2 | 14 | — | |
| Right-of-use (leased) assets | 28 | 30 | 33 | — | — | — | |
| Goodwill | 278 | 278 | 578 | 4.0 | 4.0 | — | |
| Other intangible assets | 165 | 203 | 245 | 0.6 | 2.1 | — | |
| Total assets | 788 | 903 | 1,286 | 476 | 73 | — | |
| Accounts payable | 14 | 10 | 7.8 | 7.4 | 5.3 | — | |
| Current liabilities | 108 | 119 | 112 | 79 | 70 | — | |
| Lease liabilities (non-current) | 26 | 27 | 32 | — | — | — | |
| Total liabilities | 343 | 429 | 430 | 85 | 97 | — | |
| Retained earnings | −1,054 | −954 | −495 | −372 | −321 | — | |
| Shareholders' equity | 445 | 474 | 856 | 391 | −257 | −231 | |
| Total liabilities and equity | 788 | 903 | 1,286 | 476 | 73 | — | |
| Shares outstanding | 78 | 73 | 67 | 56 | 6.0 | — | |
| Cash-flow statement | |||||||
| Depreciation and amortization | 45 | 46 | 43 | 8.2 | 8.5 | 9.4 | |
| Share-based compensation | 61 | 73 | 73 | 9.6 | 6.0 | 5.7 | |
| Cash from operating activities | −16 | −41 | −62 | −25 | −34 | −17 | |
| Capital expenditure | −4.9 | −2.1 | −2.5 | −2.0 | −3.3 | −1.2 | |
| Acquisitions, net of cash acquired | 0 | 0 | −260 | — | −0.2 | — | |
| Cash from investing activities | −64 | −7.2 | −264 | −2.4 | −3.5 | −3.1 | |
| Debt issued | 0 | 0 | 288 | 51 | 1.7 | 3.0 | |
| Debt repaid | — | — | — | −73 | — | −5.0 | |
| Shares issued | — | — | — | 439 | — | — | |
| Cash from financing activities | −56 | 3.2 | 258 | 428 | 28 | 49 | |
| Change in cash | −135 | −45 | −68 | 401 | −9.5 | 29 | |
| Report | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | |
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
As of Nov 30, 2024
Events at Accolade, Inc.#
What the company reported to the SEC within four business days (Form 8-K), newest first.
No warning signs in the last three years: no bankruptcy, delisting notice, withdrawn financial statements, auditor change, cybersecurity incident, debt called early or impairment was reported.
Taken over and delisted 1 · Change in control 1 · Acquisition or sale completed 1 · Directors and officers 2 · Material agreement 3 · Shareholder rights changed 1 · Bylaws or fiscal year changed 1 · Shareholder vote 4 · Results announced 14
| Filed | What happened | Filing |
|---|---|---|
| Taken over and delistedChange in controlAcquisition or sale completedDirectors and officersMaterial agreementShareholder rights changedBylaws or fiscal year changed | 8-K | |
| Shareholder vote | 8-K | |
| Material agreementResults announced | 8-K | |
| Results announced | 8-K | |
| Shareholder vote | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Shareholder vote | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Shareholder vote | 8-K | |
| Material agreement | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K |
As of Apr 8, 2025
Acquisitions and funding#
3 acquisitions, $841 M paid where reported · 6 private funding rounds before listing
Businesses it acquired
| Acquired | Acquisition date | Completion | Price | Stake | Source |
|---|---|---|---|---|---|
| Acquisition of 2nd.MD | 2021 | — | $420 M | — | Annual report |
| PlushCare | 2021 | — | $414 M | — | Annual report |
| MD Insider Inc | 2019 | — | $6 M | — | Annual report |
Private share sales · funding history
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Sep 2021 | $11 M | Issued in a merger or acquisition | $10 to $50 million | 1 | equity | SEC |
| Jun 2021 | $325 M | Issued in a merger or acquisition | $250 million to $1 billion | 79 | equity | SEC |
| Mar 2021 | $130 M | Issued in a merger or acquisition | $50 to $250 million | 43 | equity | SEC |
| Oct 2019 | $20 M | No. 6 | $10 to $50 million | 1 | equity, options | SEC |
| Mar 2018 | $27 M | No. 5 | $10 to $50 million | 17 | equity, options | SEC |
| Jul 2016 | $55 M | No. 4 | $50 to $250 million | 4 | equity, options | SEC |
| Jul 2015 | $39 M | No. 3 | $10 to $50 million | 5 | equity | SEC |
| Apr 2014 | $3 M | Issued in a merger or acquisition | $2 to $10 million | 1 | equity | SEC |
| Dec 2013 | $30 M | No. 2 | $10 to $50 million | 17 | equity | SEC |
| Jun 2010 | $17 M | No. 1 | $10 to $50 million | 17 | equity | SEC |
H-1B hiring at Accolade, Inc.#
10 labor condition applications certified in fiscal 2025 for 10 positions, at a median wage of $118 K a year.
| Job title | Positions | Median wage offered |
|---|---|---|
| SR. SOFTWARE ENGINEERSoftware Developers | 3 | $124 K |
| SR. BUSINESS INTELLIGENCE DEVELOPERSoftware Developers | 2 | $109 K |
| SR. PRODUCT ANALYSTOperations Research Analysts | 2 | $103 K |
| PRINCIPAL SOFTWARE ENGINEER ISoftware Developers | 1 | $146 K |
| SOFTWARE ENGINEER ISoftware Developers | 1 | $111 K |
| SOFTWARE ENGINEER IISoftware Developers | 1 | $118 K |
Where: Seattle, WA 5 · Georgetown, TX 2 · Plymouth Meeting, PA 2 · Argyle, TX 1
| Fiscal year | Certified | Positions | Median wage | Filed |
|---|---|---|---|---|
| FY2025 | 10 | 10 | $118 K | 10 |
| FY2024 | 12 | 12 | $122 K | 13 |
| FY2023 | 10 | 10 | $129 K | 10 |
| FY2022 | 19 | 19 | $161 K | 19 |
| FY2021 | 10 | 10 | $106 K | 10 |
| FY2020 | 5 | 5 | $99 K | 5 |
How Accolade, Inc. compares in Healthcare Information Services
- Revenue$414 M · higher than 61% of 71
- Net margin-24.1% · higher than 24% of 69
- Revenue growth14.1% · higher than 67% of 40
Peer comparison · Healthcare Information Services
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| Accolade, Inc.🇺🇸 | $860 M | — | -24.1% | +14.1% |
| Veeva Systems Inc.🇺🇸 | $50.2 B | 49.5× | 29.4% | +16.3% |
| Pro Medicus Limited🇦🇺 | $14.4 B | 81.3× | — | — |
| 10x Genomics, Inc.🇺🇸 | $9.4 B | — | -10.8% | +5.3% |
| HealthEquity, Inc.🇺🇸 | $8.3 B | 35.3× | 17.4% | +9.5% |
| M3, Inc.🇯🇵 | $7.1 B | 21.5× | 14.0% | — |
| Doximity, Inc.🇺🇸 | $5.5 B | 39.5× | 21.1% | +13.1% |
| Privia Health Group, Inc.🇺🇸 | $2.8 B | 80.9× | 1.4% | +22.3% |
| Winning Health Technology Group Co., Ltd.🇨🇳 | $2.3 B | 41.3× | 13.8% | — |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
- Veeva Systems Inc.$50.2 B
- Pro Medicus Limited$14.4 B
- 10x Genomics, Inc.$9.4 B
- HealthEquity, Inc.$8.3 B
- M3, Inc.$7.1 B
- Doximity, Inc.$5.5 B
How current the figures are
- Market cap:
- Jan 5, 2024 (last known)
- Annual results:
- For year ending February-2024
- Balance sheet:
- As of February-2024
- Employees:
- As on Feb-2023
- Profile updated:
- Nov 14, 2026
How each figure is collected: methodology. Market caps in US dollars unless you switch the currency.
Work at Accolade, Inc.? Verify and update this profile — free
Show Accolade, Inc.'s ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.